BIORA THERAPEUTICS Stock Price, News & Analysis

Biora Therapeutics, historically trading under the ticker BIOR, is described in recent company communications as a clinical-stage biotech company focused on reimagining therapeutic delivery. The company has developed smart pill-based platforms intended to change how therapies are delivered in gastrointestinal and systemic diseases. According to multiple news releases, Biora Therapeutics has concentrated its efforts on two main oral drug-device platforms, NaviCap™ and BioJet™, which are designed to enable targeted or needle-free delivery of therapeutics.

Core Therapeutic Delivery Platforms

Biora Therapeutics states that it is developing the NaviCap™ platform for colon-targeted treatment of inflammatory bowel disease (IBD). Company descriptions explain that NaviCap is designed to improve patient outcomes by delivering treatment directly to the site of disease in the gastrointestinal tract. In corporate updates, Biora notes that its NaviCap work includes BT-600, and that Phase 1 clinical trial results for BT-600 have been presented at a major gastroenterology meeting, with the data suggesting the potential to move to larger clinical trials in ulcerative colitis patients.

The company also highlights the BioJet™ platform, described as an oral delivery platform for large molecules that is designed to replace injection with needle-free, oral delivery. Biora characterizes BioJet as a swallowable autoinjector that uses liquid jet injection to deliver drug into the submucosa of the small intestine. Company materials state that BioJet is intended for macromolecules such as proteins, peptides, and nucleic acids, using standard liquid drug formulations.

BioJet Swallowable Autoinjector Technology

In several news releases, Biora Therapeutics provides additional detail on the BioJet platform. The device is described as a swallowable, needle-free autoinjector that autonomously delivers drug into the small intestine using a liquid jet. Biora reports that the BioJet device has been tested in numerous in vivo studies with internal and collaborator molecules, and that it is designed to achieve oral bioavailability for macromolecules compared to injectable routes.

The company has emphasized development of a smaller, 00-size BioJet device. According to Biora, this 00-size capsule maintains or increases payload capacity while reducing overall size compared with a larger 000-size capsule. Company communications state that the 00-size BioJet device is designed to deliver standard liquid formulations with a capacity greater than 300 microliters and to enable doses greater than 50 milligrams. Biora also notes that this smaller device format is intended to be compatible with non-human primate testing and human clinical trial requirements, and that it has been engineered with automated manufacturing, including sterile fill and finish, in mind.

NaviCap Platform and Gastrointestinal Focus

For its NaviCap platform, Biora Therapeutics describes a colon-targeted oral delivery approach for IBD. The company states that NaviCap is designed to deliver therapy at the site of disease in the gastrointestinal tract, with the goal of improving outcomes for conditions such as ulcerative colitis. In a corporate update, Biora reports that Phase 1 clinical trial results for BT-600, a NaviCap-based program, were presented at a major gastroenterology conference and that the data may support proceeding to a larger clinical trial in ulcerative colitis patients.

Company communications further indicate that Biora’s clinical and regulatory experience with the NaviCap platform has informed and streamlined development work on the BioJet platform, particularly in designing devices suitable for clinical use and manufacturing.

Corporate Status and Restructuring

Later news reports describe significant changes in Biora Therapeutics’ corporate status. On December 30, 2024, the company announced that it had filed a voluntary petition under chapter 11 of the U.S. Bankruptcy Code in the District of Delaware, with an agreement from certain prepetition creditors to provide financing to support a court-supervised sale process. The company indicated that this process was intended to strengthen its balance sheet and support the next stage of product development, with lenders serving as a stalking horse bidder for its assets.

On March 31, 2025, Biora Therapeutics announced the successful completion of its court-supervised restructuring. In that release, the company stated that it had emerged from the restructuring as a privately held company, with an improved balance sheet and new long-term financing to support development of the BioJet platform. The same announcement explains that ownership of the company transitioned to certain lenders and that the company’s existing common shares were cancelled pursuant to a Plan of Reorganization. As a result, Biora Therapeutics describes itself as a leaner, privately held company focused on advancing its swallowable autoinjector technology.

Focus Areas and Development Strategy

Across its communications, Biora Therapeutics consistently describes its focus on oral drug-device combinations intended to address challenges in therapeutic delivery. For BioJet, the company highlights the goal of replacing injectable administration of large molecules with a swallowable, needle-free device capable of delivering substantial payloads in the small intestine. For NaviCap, Biora emphasizes targeted delivery in the colon for IBD treatment.

The company has also discussed its approach to partnering and collaborations. In a corporate update, Biora notes that it has engaged with pharmaceutical collaborators around its BioJet technology and has considered shifting from a co-development model toward licensing of the 00-size BioJet device across multiple verticals. In other communications, Biora mentions collaborations with large pharmaceutical companies and participation in scientific and industry meetings focused on drug delivery and peptide therapeutics, where it presents data and platform updates.

Industry Context

Based on its own descriptions, Biora Therapeutics operates at the intersection of biotechnology and drug delivery, concentrating on smart pill-based platforms that combine device engineering with therapeutic development. Its work centers on enabling oral administration of therapies that are typically delivered by injection and on targeting drug delivery within the gastrointestinal tract. These efforts are reflected in repeated company statements that its platforms are designed to improve patient management of chronic diseases and to provide needle-free alternatives for macromolecule delivery.